Description GA101 (3rd Generation Anti-CD20) is a glycoengineered, humanized, type II anti-CD20 monoclonal antibody. Glycoengineeering is designed to increase antibody-dependent cytotoxicity (ADCC) when compared to rituximab. GA101 binds with high affinity to a type II epitope on CD20 and is characterized by reduced complement-dependent cytotoxicity (CDC) and strongly enhanced direct cell death.

Development Status Phase I/II clinical trials are ongoing evaluating GA101 for CD20-positive B-cell hematologic malignancies: including indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Phase III clinical trials evaluating GA101 for indolent non-Hodgkin's lymphoma and front-line chronic lymphocytic leukemia are planned.

This molecule is being developed in collaboration with Biogen Idec Inc.

Additional Information on Clinical Trials For inquiries about our clinical trials, please submit a request through our information request form or call (888) 662-6728.

National Institutes of Health Website: www.clinicaltrials.gov

July 2009